References of "Fundamental & Clinical Pharmacology"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCan beta2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?
Zhang, Wen-Hui; Zhang, Yong; Cui, Yong-Yao et al

in Fundamental & Clinical Pharmacology (2012), 26(1), 118-134

Chronic obstructive pulmonary disease (COPD) has become a global epidemic disease with an increased morbidity and mortality in the world. Inflammatory process progresses and contributes to irreversible ... [more ▼]

Chronic obstructive pulmonary disease (COPD) has become a global epidemic disease with an increased morbidity and mortality in the world. Inflammatory process progresses and contributes to irreversible airflow limitation. However, there is no available therapy to better control the inflammatory progression and therefore to reduce the exacerbations and mortality. Thus, the development of efficient anti-inflammatory therapies is a priority for patients with COPD. beta(2) -Adrenoceptor agonists and anticholinergic agents are widely used as first line drugs in management of COPD because of their efficient bronchodilator properties. At present, many studies in vitro and some data obtained in laboratory animals reveal the potential anti-inflammatory effects of these bronchodilators but their protective role against chronic inflammation and the development of emphysema in patients with COPD remains to be investigated. The anti-inflammatory effects of theophylline at low doses have also been identified. Beneficial interactions between glucocorticoids and bronchodilators have been reported, and signaling pathways explaining these synergistic effects begin to be understood, especially for theophylline. Recent data demonstrating interactions between anticholinergics with beta(2) -adrenoceptor agonists aiming to better control the pulmonary inflammation and the development of emphysema in animal models of COPD justify the priority to investigate the interactive effects of a tritherapy associating corticoids with the two main categories of bronchodilators. [less ▲]

Detailed reference viewed: 24 (4 ULg)
Full Text
Peer Reviewed
See detailEffects of ipratropium bromide on repeated cadmium inhalation-induced lune inflammation and airspace enlargement in rats
Zhang, W. H.; Fievez, Laurence ULg; Cheu, Esteban ULg et al

in Fundamental & Clinical Pharmacology (2010), 10

Detailed reference viewed: 28 (3 ULg)
Peer Reviewed
See detailAnti-inflammatory effects of ipratropium bromide in rats with cadmium-induced acute pulmonary inflammation
Zhang, Yinghong ULg; Fievez, Laurence ULg; Cheu, Esteban ULg et al

in Fundamental & Clinical Pharmacology (2008), 22(1), 7

Detailed reference viewed: 46 (3 ULg)
Peer Reviewed
See detailRole of beta 2-receptors in the anti-inflammatory effects of formoterol in rats with cadmium-induced acute pulmonary inflammation
Zhang, W.; Fievez, Laurence ULg; Cheu, Esteban ULg et al

in Fundamental & Clinical Pharmacology (2008), 227

Detailed reference viewed: 35 (8 ULg)
Peer Reviewed
See detailAnti-inflammatory effects of formoterol in rats after a single dose inhalation of nebulized cadmium
Zhang, W. H.; Fievez, Laurence ULg; Cheu, Esteban ULg et al

in Fundamental & Clinical Pharmacology (2007), 74

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailPreclinical and clinical pharmacology of alcohol dependence
Tambour, Sophie ULg; Quertemont, Etienne ULg

in Fundamental & Clinical Pharmacology (2007), 21(1), 9-28

In recent years, advances in neuroscience led to the development of new medications to treat alcohol dependence and especially to prevent alcohol relapse after detoxification. Whereas the earliest ... [more ▼]

In recent years, advances in neuroscience led to the development of new medications to treat alcohol dependence and especially to prevent alcohol relapse after detoxification. Whereas the earliest medications against alcohol dependence were fortuitously discovered, recently developed drugs are increasingly based on alcohol's neurobiological mechanisms of action. This review discusses the most recent developments in alcohol pharmacotherapy and emphasizes the neurobiological basis of anti-alcohol medications. There are currently three approved drugs for the treatment of alcohol dependence with quite different mechanisms of action. Disulfiram is an inhibitor of the enzyme aldehyde dehydrogenase and acts as an alcohol-deterrent drug. Naltrexone, an opiate antagonist, reduces alcohol craving and relapse in heavy drinking, probably via a modulation of the mesolimbic dopamine activity. Finally, acamprosate helps maintaining alcohol abstinence, probably through a normalization of the chronic alcohol-induced hyperglutamatergic state. In addition to these approved medications, many other drugs have been suggested for preventing alcohol consumption on the basis of preclinical studies. Some of these drugs remain promising, whereas others have produced disappointing results in preliminary clinical studies. These new drugs in the field of alcohol pharmacotherapy are also discussed, together with their mechanisms of action. [less ▲]

Detailed reference viewed: 39 (9 ULg)
Peer Reviewed
See detailEffects of the MMP inhibitor GM-6001 on emphysema development, infllammation and MMPs activity induced by cadmium in rats
Fievez, Laurence ULg; Kirschvinck, N.; Belleflamme, N. et al

in Fundamental & Clinical Pharmacology (2006), 20

Detailed reference viewed: 17 (0 ULg)
Peer Reviewed
See detailIn vitro pharmacological activity of salbutamol acetonide on the isolated guinea-pig trachea and porcine bronchus
Leemans, Jérôme ULg; Kirschvink, Nathalie; Delvaux, F. et al

in Fundamental & Clinical Pharmacology (2005), 19

Detailed reference viewed: 18 (6 ULg)
Peer Reviewed
See detailEvaluation of the bronchoprotective effects of inhaled salmeterol, fenoterol and oxitropium in healthy cats
Kirschvink, Nathalie; Leemans, Jérôme ULg; Delvaux, F. et al

in Fundamental & Clinical Pharmacology (2005), 19

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailSome effects of proanthocyanidins isolated from Ribes nigrum on the cardiovascular system in the rat.
Garbacki, Nancy ULg; Damas, Jacques ULg

in Fundamental & Clinical Pharmacology (2004), 18

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailSynthésis and pharmacological evaluation of original thromboxane A2 receptor antagonists derived from BM-573
Hanson, Julien ULg; Renard, Jean-François ULg; Neven, P. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailDesign and pharmacological evaluation of recently developed 6-substituted 3-bromophenyl 2-oxo-2H-1-benzopyran 3-carboxylate derivatives as putative inhibitors of cell invasion
Kempen, I.; Frankenne, F.; Telliez, A. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailIdentification of COX-2 selective inhibitor
Michaux, C.; Julémont, F.; de Leval, X. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailEffects of cromakalim analogues on rat pancreatic B-cells, rat aorta rings and rat uterus. Study of their mechanism of action as potassium channel activators
Sebille, S.; Boverie, S.; Becker, B. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailNew analogues of the KATP channel opener cromakalim : synthesis and pharmacological evaluation on rat pancreatic B-cells and rat aorta rings
Sebille, S.; De Tullio, Pascal ULg; Antoine, M. H. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 32 (4 ULg)
Full Text
Peer Reviewed
See detailCharacterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 3 (1 ULg)